Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose.

@article{Horwitz2010ParathyroidHP,
  title={Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose.},
  author={Mara J. Horwitz and Mary Beth Tedesco and Adolfo Garcia-Oca{\~n}a and Susan M. Sereika and Linda Prebehala and Alessandro Bisello and Bruce W. Hollis and Caren M. Gundberg and Andrew Francis Stewart},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2010},
  volume={95 3},
  pages={1279-87}
}
CONTEXT PTH is the only approved skeletal anabolic agent for the treatment of human osteoporosis. Unlike PTH, which is a mixed anabolic and catabolic agent, PTHrP displays features suggesting that it may be a pure anabolic agent when intermittently administered. The full dose range of PTHrP is unknown. OBJECTIVES The primary objective of the study was to define the complete therapeutic window and dose-limiting toxicities of PTHrP. The secondary objective was to determine whether PTHrP retains… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Investigational anabolic therapies for osteoporosis.

Expert opinion on investigational drugs • 2010
View 5 Excerpts
Highly Influenced

Osteoporosis: what's new and on the horizon.

View 7 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Exogenous PTH and endogenous 1,25-dihydroxyvitamin D are complementary in inducing an anabolic effect on bone.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2008

A cross-sectional study of bone turnover markers in healthy premenopausal women

AE de Papp, HG Bone, +5 authors RE Reitz
Bone • 2007

Changes in 25-hydroxy- and 1,25-dihydroxy-vitamin D during treatment with teriparatide

F Cosman, B Dawson-Hughes, P Chen, JH Krege
J Bone Miner Res • 2007

Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2005

Similar Papers

Loading similar papers…